secwatch.observer — SEC 8-K summary
======================================

Issuer:     Carisma Therapeutics Inc. (CARM)
CIK:        0001485003
Form:       8-K
Filed at:   2023-02-01T23:59:59+00:00
Accession:  0001485003-23-000020
Event type: litigation
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Class action securities litigation settlement receives final court approval
---------------------------------------------------------------------------

- U.S. District Court for Southern District of New York granted final approval on January 31, 2023.
- Settlement resolves consolidated shareholder class action In re Sesen Bio, Inc. Securities Litigation.
- Derivative litigation previously received final approval by Massachusetts court on November 9, 2022.
- Settlement terms were previously disclosed in August 2022 Form 8-K.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1485003/000148500323000020/0001485003-23-000020-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1485003/000148500323000020/sesn-20230131.htm
  HTML page:      https://secwatch.observer/filing/0001485003-23-000020

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer